A potential therapeutic target is the TBXT gene (also known as brachyury), which is amplified in 7%, duplicated in 27%, and overexpressed in more than 90% of cases (5, 6) and has been identified as the key driver of chordoma development and progression (5, 7, 8). Here, TBXT is linked to chordoma.